Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET to report third quarter results for the period ended September 30, 2025 and provide a business update.
Participants may register for the live call, access the audio webcast under Events and Presentations on Atea's Investor Relations site at ir.ateapharma.com, or join by telephone using the provided U.S. and international dial‑in numbers and conference ID 10203461. An archive of the webcast will be posted about two hours after the call and will remain available for at least 90 days.
Atea Pharmaceuticals (Nasdaq: AVIR) terrà una conference call in diretta e una webcast audio mercoledì 12 novembre 2025 alle 16:30 ET per riportare i risultati del terzo trimestre per il periodo chiuso al 30 settembre 2025 e fornire un aggiornamento sull'attività.
I partecipanti possono registrarsi per la chiamata in diretta, accedere al webcast audio nella sezione Eventi e Presentazioni sul sito degli Investor Relations di Atea all'indirizzo ir.ateapharma.com, oppure unirsi telefonicamente usando i numeri di accesso disponibili negli Stati Uniti e a livello internazionale e conference ID 10203461. Un archivio del webcast sarà pubblicato circa due ore dopo la chiamata e rimarrà disponibile per almeno 90 giorni.
Atea Pharmaceuticals (Nasdaq: AVIR) organizará una llamada de conferencia en vivo y una webcast de audio el miércoles 12 de noviembre de 2025 a las 4:30 p.m. ET para reportar los resultados del tercer trimestre para el periodo que terminó el 30 de septiembre de 2025 y proporcionar una actualización comercial.
Los participantes pueden registrarse para la llamada en vivo, acceder al webcast de audio en la sección Eventos y Presentaciones en el sitio de Relaciones con Inversores de Atea en ir.ateapharma.com, o unirse por teléfono utilizando los números de marcación de EE. UU. e internacionales y conference ID 10203461. Se publicará un archivo del webcast aproximadamente dos horas después de la llamada y permanecerá disponible por al menos 90 días.
Atea Pharmaceuticals (나스닥: AVIR)는 2025년 11월 12일 수요일 오후 4:30(동부 표준시)에 라이브 컨퍼런스 콜 및 오디오 웹캐스트를 주최하여 2025년 9월 30일 종료 기간의 3분기 실적과 사업 업데이트를 발표합니다.
참가자는 라이브 콜 등록, 또는 Atea의 투자자 관계 사이트의 이벤트 및 프레젠테이션 섹션에서 오디오 웹캐스트에 접속하거나 미국 및 국제 다이얼 인 번호 및 컨퍼런스 ID 10203461를 이용해 전화로 참여할 수 있습니다. 웹캐스트의 아카이브는 통화 직후 약 두 시간 후에 게시되며 최소 90일간 이용 가능
Atea Pharmaceuticals (Nasdaq: AVIR) organisera une conférence téléphonique en direct et une webdiffusion audio le mercredi 12 novembre 2025 à 16 h 30 HE pour diffuser les résultats du troisième trimestre pour la période se terminant le 30 septembre 2025 et fournir une mise à jour sur les activités.
Les participants peuvent s'inscrire pour l'appel en direct, accéder à la webdiffusion audio dans la rubrique Événements et Présentations sur le site des Relations avec les Investisseurs d'Atea à l'adresse ir.ateapharma.com, ou rejoindre par téléphone en utilisant les numéros d'accès américains et internationaux fournis et la conference ID 10203461. Une archive du webcast sera publiée environ deux heures après l'appel et restera disponible pendant au moins 90 jours.
Atea Pharmaceuticals (Nasdaq: AVIR) lädt zu einer Live-Konferenzschaltung und einem Audio-Webcast am Mittwoch, den 12. November 2025 um 16:30 Uhr ET ein, um die Ergebnisse des dritten Quartals für den Zeitraum zum 30. September 2025 bekanntzugeben und ein Unternehmensupdate zu geben.
Teilnehmer können sich für den Live-Anruf registrieren, den Audio-Webcast unter Events and Presentations auf der Investor Relations-Seite von Atea unter ir.ateapharma.com aufrufen oder telefonisch über die in den USA und international bereitgestellten Wählnummern und Conference ID 10203461 teilnehmen. Ein Archiv des Webcasts wird ca. zwei Stunden nach dem Anruf veröffentlicht und bleibt mindestens 90 Tage verfügbar.
Atea Pharmaceuticals (ناسداك: AVIR) ستعقد مكالمة هاتفية حية وبث صوتي عبر الويب في الأربعاء 12 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة للإبلاغ عن نتائج الربع الثالث للفترة المنتهية في 30 سبتمبر 2025 وتقديم تحديث أعمال.
يمكن للمشاركين التسجيل للمكالمة الحية، والوصول إلى البث الصوتي عبر الويب ضمن الأحداث والعروض على موقع علاقات المستثمرين التابع لـ Atea على ir.ateapharma.com، أو الانضمام عن طريق الهاتف باستخدام أرقام الاتصال الأمريكية والدولية المقدمة ومعرف المؤتمر 10203461. ستُدرج أرشيف البث عبر الويب بعد حوالي ساعتين من انتهاء المكالمة وسيبقى متاحًا لمدة لا تقل عن 90 يومًا.
- None.
- None.
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12, 2025, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2025, and to provide a business update.
To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please dial 1-877-300-8521 (U.S.) or 1-412-317-6026 (International) and use conference ID number 10203461. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s lead program is the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company’s plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
When will Atea Pharmaceuticals (AVIR) report Q3 2025 results?
What period does Atea's Q3 2025 financial report cover?
How can investors access the Atea (AVIR) conference call and webcast on November 12, 2025?
What are the dial‑in numbers and conference ID to join Atea's November 12, 2025 call?
When and how long will the Atea (AVIR) webcast archive be available after the November 12, 2025 call?
What will Atea discuss on the November 12, 2025 conference call?
